At the AAIC conference held 27 July to 1 August in Philadelphia, microglial epigenetics stood in the limelight. Microglia are infamous for their dynamic and varied responses to different threats they ...

Voyager Therapeutics has unveiled a new program focused on Alzheimer’s disease (AD) that utilizes a proprietary IV-delivered TRACER™ capsid to target the APOE gene, specifically aiming to reduce the ...

A new study, published today in Nature Communications, offers clues into how APOE isoforms differentially affect human microglia function in Alzheimer's disease. The study, led by Dr. Sarah Marzi and ...

Late-onset Alzheimer's disease is a debilitating, progressive neurodegenerative disease that affects about 7 million Americans, a figure that is expected to nearly double by 2050, according to the ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Super agers show that sharp memory into the 80s is possible, and a protective APOE gene ...

The APOE Christchurch variant was identified as a candidate protective factor against Alzheimer’s disease in a carrier of the PSEN1 “Paisa” mutation—the most common cause of familial autosomal ...

Scientists have linked the APOE gene, which codes for a protein that carries cholesterol in the bloodstream, to Alzheimer’s disease since the 1990s, but the new data suggest that the field has ...